COSCIENS Biopharma Inc. Common Stock
CSCI
CSCI was delisted on the 3rd of September, 2025.
13 hedge funds and large institutions have $2.31M invested in COSCIENS Biopharma Inc. Common Stock in 2016 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 5 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
0% more funds holding
Funds holding: 13 → 13 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
19% less capital invested
Capital invested by funds: $2.86M → $2.31M (-$545K)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $307K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Group One Trading
Chicago,
Illinois
|
+$87.6K |
| 2 |
Morgan Stanley
New York
|
+$45.2K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$29.1K |
| 4 |
Creative Planning
Overland Park,
Kansas
|
+$17.5K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$17.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$697K |
| 2 |
Renaissance Technologies
New York
|
-$140K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
-$46K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$35K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$4.91K |
CSCI Hedge Fund Activity: Q3 2016 in Review
13 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in COSCIENS Biopharma Inc. Common Stock (CSCI) for Q3 2016, worth a combined $2.31M — down 19% from $2.86M a quarter earlier.
Fund positioning in CSCI was balanced in Q3 2016: 5 funds opened new positions, 5 closed out, 4 added to existing stakes and 3 trimmed.
The largest buyer was Group One Trading, adding an estimated $87.6K. The largest seller was Sabby Management, cutting an estimated $697K.
- 13 institutional investors held COSCIENS Biopharma Inc. Common Stock (CSCI) as of Q3 2016, unchanged from Q2 2016.
- Funds reported $2.31M of COSCIENS Biopharma Inc. Common Stock stock for Q3 2016, down 19% quarter-over-quarter.
- 5 funds opened new COSCIENS Biopharma Inc. Common Stock positions in Q3 2016 and 5 closed out, a net change of 0 holders.
- The largest COSCIENS Biopharma Inc. Common Stock buyer in Q3 2016 was Group One Trading, an estimated $87.6K added.
- The largest COSCIENS Biopharma Inc. Common Stock seller in Q3 2016 was Sabby Management, an estimated $697K sold.
Based on aggregated 13F filings for Q3 2016.